肠道菌群与帕金森病关系的研究进展
Research Progress on the Relationship between Gut Microbiome and Parkinson’s Disease
摘要: 帕金森病(Parkinson’s disease, PD)是一种中枢神经系统的退行性疾病，对其进行精确地诊断依然是一个具有挑战性的任务。研究发现帕金森病患者的肠道微生物群显示出独特的变化，这一发现为PD的诊断、治疗提供新思路。本文将围绕肠道菌群在帕金森病中的作用，包括机制研究、治疗选择进行阐述，以及针对PD的肠道菌群干预措施等方面的最新研究进展，以期为帕金森病的预防和治疗的新策略提供新的依据。
Abstract: Parkinson’s disease (PD) is a degenerative disease of the central nervous system, and accurate diagnosis of PD remains a challenging task. Research has found that the gut microbiome of PD patients shows unique changes, which provides new insights into the diagnosis and treatment of PD. This article will discuss the latest research progress on the role of gut microbiota in PD, including mechanism studies, treatment options, and interventions for PD-targeted gut microbiota, with the aim of providing new evidence for the prevention and treatment of PD.
文章引用：克力比奴尔·塞地尔丁, 杨新玲. 肠道菌群与帕金森病关系的研究进展[J]. 临床医学进展, 2024, 14(12): 1287-1293. https://doi.org/10.12677/acm.2024.14123217

参考文献

[1] Lajoie, A.C., Lafontaine, A. and Kaminska, M. (2021) The Spectrum of Sleep Disorders in Parkinson Disease. Chest, 159, 818-827. [Google Scholar] [CrossRef] [PubMed]
[2] 刘疏影, 陈彪. 帕金森病流行现状[J]. 中国现代神经疾病杂志, 2016, 16(2): 98-101.
[3] Olanow, C.W. and Brundin, P. (2013) Parkinson’s Disease and Alpha Synuclein: Is Parkinson’s Disease a Prion‐Like Disorder? Movement Disorders, 28, 31-40. [Google Scholar] [CrossRef] [PubMed]
[4] Sun, M. and Shen, Y. (2018) Dysbiosis of Gut Microbiota and Microbial Metabolites in Parkinson’s Disease. Ageing Research Reviews, 45, 53-61. [Google Scholar] [CrossRef] [PubMed]
[5] Tan, A.H., Lim, S., Chong, K.K., A Manap, M.A.A., Hor, J.W., Lim, J.L., et al. (2021) Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. Neurology, 96, e772-e782. [Google Scholar] [CrossRef] [PubMed]
[6] Dafsari, H.S., Martinez‐Martin, P., Rizos, A., Trost, M., dos Santos Ghilardi, M.G., Reddy, P., et al. (2019) Euroinf 2: Subthalamic Stimulation, Apomorphine, and Levodopa Infusion in Parkinson’s Disease. Movement Disorders, 34, 353-365. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E. and Pettersson, S. (2021) The Role of Gut Dysbiosis in Parkinson’s Disease: Mechanistic Insights and Therapeutic Options. Brain, 144, 2571-2593. [Google Scholar] [CrossRef] [PubMed]
[8] Paillusson, S., Clairembault, T., Biraud, M., Neunlist, M. and Derkinderen, P. (2013) Activity‐Dependent Secretion of Alpha‐Synuclein by Enteric Neurons. Journal of Neurochemistry, 125, 512-517. [Google Scholar] [CrossRef] [PubMed]
[9] Perez-Pardo, P., Dodiya, H.B., Engen, P.A., Naqib, A., Forsyth, C.B., Green, S.J., et al. (2018) Gut Bacterial Composition in a Mouse Model of Parkinson’s Disease. Beneficial Microbes, 9, 799-814. [Google Scholar] [CrossRef] [PubMed]
[10] Barichella, M., Severgnini, M., Cilia, R., Cassani, E., Bolliri, C., Caronni, S., et al. (2018) Unraveling Gut Microbiota in Parkinson’s Disease and Atypical Parkinsonism. Movement Disorders, 34, 396-405. [Google Scholar] [CrossRef] [PubMed]
[11] Cersosimo, M.G., Raina, G.B., Pecci, C., Pellene, A., Calandra, C.R., Gutiérrez, C., et al. (2012) Gastrointestinal Manifestations in Parkinson’s Disease: Prevalence and Occurrence before Motor Symptoms. Journal of Neurology, 260, 1332-1338. [Google Scholar] [CrossRef] [PubMed]
[12] Scheperjans, F., Aho, V., Pereira, P.A.B., Koskinen, K., Paulin, L., Pekkonen, E., et al. (2014) Gut Microbiota Are Related to Parkinson’s Disease and Clinical Phenotype. Movement Disorders, 30, 350-358. [Google Scholar] [CrossRef] [PubMed]
[13] Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Nomoto, K., Ohno, K., et al. (2017) Progression of Parkinson’s Disease Is Associated with Gut Dysbiosis: Two-Year Follow-Up Study. PLOS ONE, 12, e0187307. [Google Scholar] [CrossRef] [PubMed]
[14] Aho, V.T.E., Pereira, P.A.B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., et al. (2019) Gut Microbiota in Parkinson’s Disease: Temporal Stability and Relations to Disease Progression. eBioMedicine, 44, 691-707. [Google Scholar] [CrossRef] [PubMed]
[15] Cilia, R., Piatti, M., Cereda, E., Bolliri, C., Caronni, S., Ferri, V., et al. (2021) Does Gut Microbiota Influence the Course of Parkinson’s Disease? A 3-Year Prospective Exploratory Study in de novo Patients. Journal of Parkinson’s Disease, 11, 159-170. [Google Scholar] [CrossRef] [PubMed]
[16] Wakabayashi, K., Takahashi, H., Takeda, S., Ohama, E. and Ikuta, F. (1988) Parkinson’s Disease: The Presence of Lewy Bodies in Auerbach’s and Meissner’s Plexuses. Acta Neuropathologica, 76, 217-221. [Google Scholar] [CrossRef] [PubMed]
[17] Hilton, D., Stephens, M., Kirk, L., Edwards, P., Potter, R., Zajicek, J., et al. (2013) Accumulation of α-Synuclein in the Bowel of Patients in the Pre-Clinical Phase of Parkinson’s Disease. Acta Neuropathologica, 127, 235-241. [Google Scholar] [CrossRef] [PubMed]
[18] Soderholm, A.T. and Pedicord, V.A. (2019) Intestinal Epithelial Cells: At the Interface of the Microbiota and Mucosal Immunity. Immunology, 158, 267-280. [Google Scholar] [CrossRef] [PubMed]
[19] Clairembault, T., Kamphuis, W., Leclair‐Visonneau, L., Rolli‐Derkinderen, M., Coron, E., Neunlist, M., et al. (2014) Enteric GFAP Expression and Phosphorylation in Parkinson’s Disease. Journal of Neurochemistry, 130, 805-815. [Google Scholar] [CrossRef] [PubMed]
[20] Schwiertz, A., Spiegel, J., Dillmann, U., Grundmann, D., Bürmann, J., Faßbender, K., et al. (2018) Fecal Markers of Intestinal Inflammation and Intestinal Permeability Are Elevated in Parkinson’s Disease. Parkinsonism & Related Disorders, 50, 104-107. [Google Scholar] [CrossRef] [PubMed]
[21] Keshavarzian, A., Green, S.J., Engen, P.A., Voigt, R.M., Naqib, A., Forsyth, C.B., et al. (2015) Colonic Bacterial Composition in Parkinson’s Disease. Movement Disorders, 30, 1351-1360. [Google Scholar] [CrossRef] [PubMed]
[22] Lin, C., Chen, C., Chiang, H., Liou, J., Chang, C., Lu, T., et al. (2019) Altered Gut Microbiota and Inflammatory Cytokine Responses in Patients with Parkinson’s Disease. Journal of Neuroinflammation, 16, Article No. 129. [Google Scholar] [CrossRef] [PubMed]
[23] Abreu, M.T. (2010) Toll-Like Receptor Signalling in the Intestinal Epithelium: How Bacterial Recognition Shapes Intestinal Function. Nature Reviews Immunology, 10, 131-144. [Google Scholar] [CrossRef] [PubMed]
[24] 张利杰, 刘燕, 郝梦蝶, 等. 肠道菌群和Toll样受体在帕金森病中的研究进展[J]. 中国实用神经疾病杂志, 2023, 26(10): 1317-1320.
[25] Terán-Ventura, E., Aguilera, M., Vergara, P. and Martínez, V. (2014) Specific Changes of Gut Commensal Microbiota and TLRs during Indomethacin-Induced Acute Intestinal Inflammation in Rats. Journal of Crohn’s and Colitis, 8, 1043-1054. [Google Scholar] [CrossRef] [PubMed]
[26] Agirman, G. and Hsiao, E.Y. (2021) Snapshot: The Microbiota-Gut-Brain Axis. Cell, 184, 2524-2524.e1. [Google Scholar] [CrossRef] [PubMed]
[27] Brzozowski, B., Mazur-Bialy, A., Pajdo, R., Kwiecien, S., Bilski, J., Zwolinska-Wcislo, M., et al. (2016) Mechanisms by Which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis. Current Neuropharmacology, 14, 892-900. [Google Scholar] [CrossRef] [PubMed]
[28] Zheng, S., Li, H., Xu, R., Miao, W., Dai, M., Ding, S., et al. (2021) Potential Roles of Gut Microbiota and Microbial Metabolites in Parkinson’s Disease. Ageing Research Reviews, 69, Article 101347. [Google Scholar] [CrossRef] [PubMed]
[29] Shin, C., Lim, Y., Lim, H. and Ahn, T. (2020) Plasma Short‐Chain Fatty Acids in Patients with Parkinson’s Disease. Movement Disorders, 35, 1021-1027. [Google Scholar] [CrossRef] [PubMed]
[30] Janeiro, M., Ramírez, M., Milagro, F., Martínez, J. and Solas, M. (2018) Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients, 10, Article 1398. [Google Scholar] [CrossRef] [PubMed]
[31] Sankowski, B., Księżarczyk, K., Raćkowska, E., Szlufik, S., Koziorowski, D. and Giebułtowicz, J. (2020) Higher Cerebrospinal Fluid to Plasma Ratio of P-Cresol Sulfate and Indoxyl Sulfate in Patients with Parkinson’s Disease. Clinica Chimica Acta, 501, 165-173. [Google Scholar] [CrossRef] [PubMed]
[32] Chen, S., Kuo, C., Kuo, H., Chen, C., Wu, W., Liou, J., et al. (2020) The Gut Metabolite Trimethylamine N‐Oxide Is Associated with Parkinson’s Disease Severity and Progression. Movement Disorders, 35, 2115-2116. [Google Scholar] [CrossRef] [PubMed]
[33] Davis, C., Bryan, J., Hodgson, J. and Murphy, K. (2015) Definition of the Mediterranean Diet; a Literature Review. Nutrients, 7, 9139-9153. [Google Scholar] [CrossRef] [PubMed]
[34] Maraki, M.I., Yannakoulia, M., Stamelou, M., Stefanis, L., Xiromerisiou, G., Kosmidis, M.H., et al. (2018) Mediterranean Diet Adherence Is Related to Reduced Probability of Prodromal Parkinson’s Disease. Movement Disorders, 34, 48-57. [Google Scholar] [CrossRef] [PubMed]
[35] Rusch, C., Beke, M., Tucciarone, L., Nieves, C., Ukhanova, M., Tagliamonte, M.S., et al. (2021) Mediterranean Diet Adherence in People with Parkinson’s Disease Reduces Constipation Symptoms and Changes Fecal Microbiota after a 5-Week Single-Arm Pilot Study. Frontiers in Neurology, 12, Article 794640. [Google Scholar] [CrossRef] [PubMed]
[36] Makki, K., Deehan, E.C., Walter, J. and Bäckhed, F. (2018) The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease. Cell Host & Microbe, 23, 705-715. [Google Scholar] [CrossRef] [PubMed]
[37] Mirzaei, H., Sedighi, S., Kouchaki, E., Barati, E., Dadgostar, E., Aschner, M., et al. (2021) Probiotics and the Treatment of Parkinson’s Disease: An Update. Cellular and Molecular Neurobiology, 42, 2449-2457. [Google Scholar] [CrossRef] [PubMed]
[38] Vendrik, K.E.W., Ooijevaar, R.E., de Jong, P.R.C., Laman, J.D., van Oosten, B.W., van Hilten, J.J., et al. (2020) Fecal Microbiota Transplantation in Neurological Disorders. Frontiers in Cellular and Infection Microbiology, 10, Article 98. [Google Scholar] [CrossRef] [PubMed]
[39] Zhang, F., Cui, B., He, X., Nie, Y., Wu, K. and Fan, D. (2018) Microbiota Transplantation: Concept, Methodology and Strategy for Its Modernization. Protein & Cell, 9, 462-473. [Google Scholar] [CrossRef] [PubMed]

为你推荐